Pharmacokinetics and safety profile of oxaliplatin
- PMID: 9609104
Pharmacokinetics and safety profile of oxaliplatin
Abstract
In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal cancer, both as a single agent and in combination with 5-fluorouracil (5-FU) and folinic acid (FA). Oxaliplatin differs from cisplatin in its lack of nephrotoxicity and from carboplatin in its hematologic toxicity being mild. The most constant acute side effect of oxaliplatin observed in clinical trials was a transient peripheral neuropathy manifesting as paresthesia and dysesthesia in the extremities, triggered or enhanced by exposure to cold. The neurosensory phenomena, dependent on the cumulative dose of oxaliplatin, affect all patients who receive doses > or = 540 mg/m2 over four cycles or more of therapy. This neurologic toxicity is also highly reversible, with 82% of patients having their neuropathy regress within 4 to 6 months and 41% experiencing complete recovery within 6 to 8 months. With these considerations in mind, the currently recommended dosing schedules for oxaliplatin are 130 mg/m2/d as a 2- to 6-hour infusion or 175 mg/m2/d as a chronomodulated infusion over 5 days, both of which are administered every 3 weeks. Oxaliplatin rapidly disappears from the plasma and is rapidly transformed into putative active species. 5-Fluorouracil and folinic acid, often used in combination with oxaliplatin, do not affect its pharmacokinetics. The favorable pharmacokinetics and safety profile of oxaliplatin contribute to its tolerability, particularly in pretreated cancer patients with reduced renal function. The reversible nature of its dose-limiting neurotoxicity and its synergistic action with 5-FU/FA make oxaliplatin an interesting agent for the treatment of colorectal cancer and for other potential indications.
Similar articles
-
Oxaliplatin-related neurotoxicity: how and why?Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. doi: 10.1016/j.critrevonc.2006.01.001. Epub 2006 Jun 27. Crit Rev Oncol Hematol. 2006. PMID: 16806962 Review.
-
Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.Anticancer Res. 2003 Nov-Dec;23(6D):5203-8. Anticancer Res. 2003. PMID: 14981990 Clinical Trial.
-
Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.J Clin Oncol. 2007 Jun 1;25(16):2274-80. doi: 10.1200/JCO.2006.08.2388. J Clin Oncol. 2007. PMID: 17538173 Clinical Trial.
-
Clinical pharmacokinetics of oxaliplatin: a critical review.Clin Cancer Res. 2000 Apr;6(4):1205-18. Clin Cancer Res. 2000. PMID: 10778943 Review.
-
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.Clin Cancer Res. 1997 Jun;3(6):891-9. Clin Cancer Res. 1997. PMID: 9815764 Clinical Trial.
Cited by
-
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.Cancer Chemother Pharmacol. 2013 Jul;72(1):85-91. doi: 10.1007/s00280-013-2171-4. Epub 2013 May 28. Cancer Chemother Pharmacol. 2013. PMID: 23712328 Free PMC article. Clinical Trial.
-
Pharmacological factors influencing anticancer drug selection in the elderly.Drugs Aging. 2003;20(10):737-59. doi: 10.2165/00002512-200320100-00003. Drugs Aging. 2003. PMID: 12875610 Review.
-
Upregulation of ERK phosphorylation in rat dorsal root ganglion neurons contributes to oxaliplatin-induced chronic neuropathic pain.PLoS One. 2019 Nov 25;14(11):e0225586. doi: 10.1371/journal.pone.0225586. eCollection 2019. PLoS One. 2019. PMID: 31765435 Free PMC article.
-
Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.EClinicalMedicine. 2021 Oct 29;41:101157. doi: 10.1016/j.eclinm.2021.101157. eCollection 2021 Nov. EClinicalMedicine. 2021. PMID: 34765950 Free PMC article.
-
Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice.Mol Pain. 2011 Apr 26;7:29. doi: 10.1186/1744-8069-7-29. Mol Pain. 2011. PMID: 21521528 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources